Conversion Therapy of Disitamab Vedotin Combined With Sintilimab and S-1 in HER2 Overexpression Gastric Cancer

NCT ID: NCT05627414

Last Updated: 2022-11-25

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE2
• Total Enrollment: 30 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-01-01
• Study Completion Date: 2025-01-01

Brief Summary

This is a phase II, one-arm study, which is aiming to evaluate the feasibility of combination of Disitamab Vedotin, Sintilimab and S-1 as conversion therapy in patients with HER2 overexpression unresectable gastric cancer .

Detailed Description

In this study, 30 HER2 overexpression unresectable gastric cancer patients will enrolle and treate with Disitamab Vedotin, Sintilimab and S-1. During the study period, imaging examinations were conducted every 6-12 weeks to evaluate the tumor and whether it reached the operable standard. The scheme and duration of postoperative adjuvant treatment were determined by the investigator according to the patient's conditions (Sintilimab was recommended to be maintained for 1 year, and other drugs were increased or decreased according to the patient's conditions). During the study, safety evaluation and effectiveness evaluation will be conducted.

Conditions

Gastric Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Disitamab Vedotin Combined With Sintilimab and S-1

30 HER2 overexpression unresectable gastric cancer patients will enrolle and treate with Disitamab Vedotin, Sintilimab and S-1. During the study period, imaging examinations were conducted every 6-12 weeks to evaluate the tumor and whether it reached the operable standard. The scheme and duration of postoperative adjuvant treatment were determined by the investigator according to the patient's conditions (Sintilimab was recommended to be maintained for 1 year, and other drugs were increased or decreased according to the patient's conditions).

Group Type: EXPERIMENTAL

Disitamab Vedotin

Intervention Type: DRUG

2.5mg/kg，IV，Q3W

Sintilimab

Intervention Type: DRUG

200 mg，IV，Q3W

S-1

Intervention Type: DRUG

40\~60mg / m2, bid, d1-14, repeated every 3 weeks.

Intraperitoneal chemotherapy with paclitaxel

Intervention Type: PROCEDURE

Paclitaxel (PTX) was used with a dose of 60mg / m2, Q3W. （Only for patients with peritoneal metastases）

Interventions

Disitamab Vedotin

2.5mg/kg，IV，Q3W

Intervention Type: DRUG

Sintilimab

200 mg，IV，Q3W

Intervention Type: DRUG

S-1

40\~60mg / m2, bid, d1-14, repeated every 3 weeks.

Intervention Type: DRUG

Intraperitoneal chemotherapy with paclitaxel

Paclitaxel (PTX) was used with a dose of 60mg / m2, Q3W. （Only for patients with peritoneal metastases）

Intervention Type: PROCEDURE

Other Intervention Names

RC48; TYVYT; Tegafur，Gimeracil and Oteracil Potassium Capsules; Paclitaxel (PTX)

Eligibility Criteria

Inclusion Criteria

• 1) Volunteer to take part in the study ;
• 2) Age 18~70 (including 70), male or female;
• 3) Gastric cancer or adenocarcinoma of gastroesophageal junction confirmed by histology and/or cytology;
• 4) Has a single initial unresectable factor. For example, peritoneal metastasis (P1),Intraperitoneal free cancer cells positive (CY1), Paraaortic lymph node metastasis, liver metastasis (≤ 3 lesions, and ≤ 5 cm for a single lesion), ovarian metastasis;
• 5) Have not received systematic treatment;
• 6) The HER2 immunohistochemistry (IHC) test result is IHC 3+or 2+, and the previous test results of the subject (confirmed by the investigator) are acceptable;
• 7) At least one assessable lesion (RECIST 1.1 );
• 8) Expected survival time ≥ 6 months;
• 9) ECOG 0-1;
• 10) Major organs are functioning normally；

Exclusion Criteria

• 1) Have a history of malignant tumors other than gastric cancer, except for the following two cases:

1. The patient has received possible curative treatment and there is no evidence of the disease within 5 years;

2. The resected skin basal cell carcinoma, skin squamous cell carcinoma, superficial bladder cancer, cervical carcinoma in situ and other carcinoma in situ were successfully received;

• 2) Suffering from diseases that affect the absorption, distribution, metabolism or clearance of the study drug (such as severe vomiting, chronic diarrhea, intestinal obstruction, absorption disorder, etc.);
• 3) Have received allogeneic stem cells or solid organ transplantation in the past;
• 4) Patients who have received other anti-tumor systemic therapy in the past (including traditional Chinese medicine with anti-tumor indications), and have been less than 4 weeks from the completion of treatment to the administration of this study, or the adverse events caused by previous treatment have not recovered to ≤ CTCAE level 1 (except hair loss and pigmentation);
• 5) Previous or current congenital or acquired immunodeficiency disease;
• 6) Active or previously recorded autoimmune diseases or inflammatory diseases (including but not limited to: autoimmune hepatitis, interstitial pneumonia, inflammatory bowel disease, systemic lupus erythematosus, vasculitis, uveitis, hypophysitis, hyperthyroidism or hypothyroidism, asthma requiring bronchodilators, etc.), vitiligo or asthma that has completely alleviated in childhood, Those who do not need any intervention after adulthood can be included;
• 7) Systemic immunosuppressive drugs were used within 2 weeks before enrollment, or were expected to be required during the study, except for the following:

d) Corticosteroids for intranasal, inhalation, external or local injection (such as intra-articular injection);

e) The dose of prednisone or other equivalent systemic corticosteroids does not exceed 10 mg/day;

f) Preventive use of corticosteroids for hypersensitivity;

• 8) Allergic to the study drug;
• 9) Thrombosis or thromboembolism events occurred in the past 6 months, such as stroke and/or transient ischemic attack, deep vein thrombosis, pulmonary embolism, etc;
• 10) Patients at risk for severe bleeding；
• 11) Cardiovascular diseases with significant clinical significance;
• 12) Other significant clinical and laboratory abnormalities, which the researchers think affect the safety evaluation;
• 13) Serious infection in active period or poorly controlled clinically;
• 14) Not recovered from the operation;
• 15) Pregnant or lactating women, and women or men with fertility who are unwilling or unable to take effective contraceptive measures;
• 16) Other situations that the investigator thinks are not suitable for inclusion.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Tianjin Medical University Cancer Institute and Hospital

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Han Liang, Master

Role: PRINCIPAL_INVESTIGATOR

ianjin Medical University Cancer Institute and Hospital

Central Contacts

Han Liang, Master

Role: CONTACT

tjlianghan@126.com

+8602223340123 ext. 1061

Xiaona Wang, Doctor

Role: CONTACT

xiaonawang@hotmail.com

+8602223340123 ext. 1061

Other Identifiers

E20221046

Identifier Type: -

Identifier Source: org_study_id